Eli Lilly Earnings Reports

Lilly reported strong Q4 2024 results with a 45% increase in revenue to $13.53 billion, driven by volume growth from Mounjaro and Zepbound. EPS surged 102% to $4.88, while non-GAAP EPS increased 114% to $5.32. Net income more than doubled year-over-year.

Eli Lilly reported a robust Q3 2024, with revenue increasing by 20% and 42% excluding the olanzapine portfolio divestiture. The growth was primarily driven by Mounjaro and Zepbound. EPS increased to $1.07 on a reported basis and $1.18 on a non-GAAP basis, both inclusive of $3.08 of acquired IPR&D charges. The company updated its 2024 revenue guidance to $45.4 to $46.0 billion and EPS guidance to $12.05 to $12.55 (reported) and $13.02 to $13.52 (non-GAAP).

Eli Lilly reported a strong Q2 2024, with revenue increasing by 36% to $11.30 billion, driven by Mounjaro, Zepbound, and Verzenio. EPS increased by 68% to $3.28 on a reported basis and by 86% to $3.92 on a non-GAAP basis. The company raised its full-year revenue guidance by $3 billion and EPS guidance accordingly.

Eli Lilly reported a strong first quarter in 2024, with revenue increasing by 26% to $8.77 billion, driven by sales of Mounjaro, Zepbound, Verzenio, and Jardiance. EPS increased by 66% to $2.48 on a reported basis and by 59% to $2.58 on a non-GAAP basis. The company raised its full-year revenue guidance by $2 billion and EPS guidance by $1.25-$1.30.

Eli Lilly reported a robust 28% increase in Q4 2023 revenue, driven by new products and growth products. EPS increased by 13% on a reported basis and 19% on a non-GAAP basis. The company issued 2024 guidance with revenue expected to be in the range of $40.4 billion to $41.6 billion.

Eli Lilly reported a strong Q3 2023, with revenue increasing by 37% driven by Mounjaro, Verzenio, and Jardiance, as well as revenue from the sale of rights for the olanzapine portfolio (Zyprexa). However, reported EPS was a loss of $0.06, and non-GAAP EPS was $0.10, both impacted by acquired IPR&D charges.

Eli Lilly's Q2 2023 financial performance was strong, with a 28% increase in revenue driven by volume growth from key products like Mounjaro, Verzenio, Jardiance, and Taltz, as well as revenue from the sale of rights for Baqsimi. The company also saw significant pipeline progress and business development activity.

Eli Lilly's Q4 2022 results showed a 9% decrease in revenue, but excluding COVID-19 antibodies, revenue increased by 5%. EPS increased by 13% on a reported basis. The company is focusing on launching new medicines and advancing its pipeline.

Eli Lilly's Q3 2022 revenue increased by 2%, driven by a 14% increase in volume, with key growth products representing 70% of revenue. The company saw a strong launch for Mounjaro, with $97.3 million in U.S. revenue. EPS increased by 32% to $1.61 on a reported basis and by 12% to $1.98 on a non-GAAP basis.

Eli Lilly's Q2 2022 revenue decreased by 4% year-over-year, but grew 6% excluding Alimta, Cialis in China, and COVID-19 antibodies. The company launched Mounjaro in the U.S. and advanced its pipeline with regulatory approvals and Priority Review designations. EPS decreased by 31% on a reported basis and 32% on a non-GAAP basis, both inclusive of acquired IPR&D and development milestone charges.

Eli Lilly's Q1 2022 revenue increased by 15%, driven by a 20% increase in volume. EPS increased by 41% to $2.10 on a reported basis and by 63% to $2.62 on a non-GAAP basis. The company updated its 2022 EPS guidance to be in the range of $7.30 to $7.45 on a reported basis and $8.15 to $8.30 on a non-GAAP basis.

Eli Lilly reported an 8% increase in revenue for Q4 2021, driven by an 11% increase in volume. Excluding COVID-19 antibodies, revenue grew by 6%. EPS decreased by 18% to $1.90 on a reported basis but increased by 8% to $2.49 on a non-GAAP basis. The company reaffirmed its 2022 EPS guidance.

Eli Lilly reported a strong third quarter in 2021, with revenue increasing by 18% driven by a 17% increase in volume. Key growth products contributed significantly to revenue growth. The company also highlighted pipeline advancements, including regulatory submissions and positive Phase 3 readouts.

Eli Lilly reported a strong second quarter in 2021, with revenue increasing by 23% driven by volume growth. Key growth products contributed significantly to revenue, and the company progressed its pipeline with positive data readouts and regulatory submissions. The company updated its 2021 financial guidance.

Eli Lilly's Q1 2021 revenue increased by 16%, driven by volume growth and key products like Trulicity and Verzenio. The company achieved significant progress in R&D, including positive data readouts for tirzepatide and donanemab. EPS decreased on a reported basis but increased on a non-GAAP basis. The 2021 EPS guidance was lowered on a reported basis and adjusted on a non-GAAP basis.

Eli Lilly's Q4 2020 revenue increased by 22% driven by volume growth of 24%. Excluding bamlanivimab revenue, revenue grew by 7%. EPS increased to $2.32 on a reported basis and $2.75 on a non-GAAP basis.

Eli Lilly's Q3 2020 revenue increased by 5% to $5.741 billion, driven by a 9% increase in volume. EPS decreased to $1.33 on a reported basis and increased to $1.54 on a non-GAAP basis. The company continues to advance the development of potential therapeutics for COVID-19.

Eli Lilly reported a 2% decrease in revenue for Q2 2020, impacted by lower realized prices and the COVID-19 pandemic. Despite this, the company achieved several R&D milestones and raised EPS guidance for the year.

Eli Lilly reported a strong first quarter with a 15% increase in revenue, driven by a 22% increase in volume. The company's performance was augmented by increased customer buying patterns and patient prescription trends due to the COVID-19 pandemic, which added approximately $250 million to revenue. EPS decreased on a reported basis but increased to $1.75 on a non-GAAP basis. The company has adjusted its EPS guidance for 2020.